BCEC

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Retrieved on: 
목요일, 4월 4, 2024
Level 3, Refractive surgery, ASCRS, BCEC, Patient, Level 2, EDT, Cataract, Society, Lens, LAL, Telescopic sight

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).

Key Points: 
  • The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
  • In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
  • At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
    Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
  • A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
화요일, 4월 2, 2024
IOP, Gland, Signs, Ciclosporin, Glaucoma, LHT, Wills Eye Hospital, ASCRS, BCEC, Patient, Telecanthus, Meibomian gland dysfunction, Doctor of Philosophy, MD, GEMINI, DED, OMNI, Signs and symptoms, Safety, Poster, Pharmaceutical industry

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points: 
  • OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
  • Lead author: Julio Echegoyen, MD, PhD
    Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
  • The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
  • Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
화요일, 4월 2, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, IOTA, ROCK, O.D, Comparison, Cell, Eye, Refractive surgery, Port, ASCRS, BCEC, Patient, Cataract, Senior, Society, Safety, PMDA, Convention center, Annual general meeting, Ophthalmology

Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.
  • “We are delighted to share additional insights into these clinical studies, in multiple sessions at the Eyecelerator and ASCRS 2024 meetings,” said Michael Goldstein, M.D., president and chief medical officer, Aurion Biotech.
  • The ABA-1 / CLARA trial is designed to assess the safety, tolerability, and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction.
  • The primary endpoint is the percentage of subjects who gain 3 lines of vision at 6 months.

ViaLase to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
화요일, 4월 2, 2024
Laser, Glaucoma, Flight, Refractive surgery, ASCRS, BCEC, Patient, Doctor of Philosophy, Cataract, Society, Safety, Physician, Annual general meeting, Medical imaging

ALISA VIEJO, Calif., April 2, 2024 /PRNewswire/ -- ViaLase, Inc ., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.

Key Points: 
  • ALISA VIEJO, Calif., April 2, 2024 /PRNewswire/ -- ViaLase, Inc ., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.
  • We are excited to share the latest clinical data demonstrating the safety and efficacy of the ViaLase Laser at ASCRS.
  • ViaLase recently announced that it had completed a Series C round of financing, which will fund continued advancement of clinical, regulatory, and commercial milestones for the ViaLase® Laser.
  • The corporate and clinical presentations are scheduled as follows:
    Location: BCEC - Meeting Level 2, Room 259A
    *The ViaLase Laser is not approved for use in the United States.

GFL Environmental Inc. Announces Secondary Offering of 17,000,000 Subordinate Voting Shares by Selling Shareholders

Retrieved on: 
수요일, 2월 28, 2024
The Company, Attention, Prospectus, Capital market, Ontario Teachers' Pension Plan, Telephone, News, TSX, RBC Capital Markets, EDGAR, Sale, Floor, BCEC, HPS, Equity capital markets, Form, Communication, Cayman, RBC, GFL, Vesey Street, Offering, Security (finance)

VAUGHAN, ON, Feb. 28, 2024 /PRNewswire/ - GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) ("GFL" or the "Company") today announced that BCEC GFL Borrower (Cayman) LP, Ontario Teachers' Pension Plan Board, GFL Borrower II (Cayman) LP, Poole Private Capital, LLC, and entities affiliated with HPS Investment Partners, LLC (collectively, the "Selling Shareholders") intend to offer for sale 17,000,000 subordinate voting shares (the "Shares").

Key Points: 
  • VAUGHAN, ON, Feb. 28, 2024 /PRNewswire/ - GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) ("GFL" or the "Company") today announced that BCEC GFL Borrower (Cayman) LP, Ontario Teachers' Pension Plan Board, GFL Borrower II (Cayman) LP, Poole Private Capital, LLC, and entities affiliated with HPS Investment Partners, LLC (collectively, the "Selling Shareholders") intend to offer for sale 17,000,000 subordinate voting shares (the "Shares").
  • GFL will not receive any proceeds from the sale of the Shares (the "Offering").
  • RBC Capital Markets, LLC and RBC Dominion Securities Inc. will act as underwriters for the Offering in the United States and Canada, respectively.
  • GFL has filed the Form F-10 registration statement (including a prospectus) with the SEC for the offering to which this communication relates.

Registration Opens for DeviceTalks Boston 2024

Retrieved on: 
금요일, 1월 19, 2024
Media, Entertainment, Podcast, Robotics, Technology, Medical Devices, Artificial Intelligence, Health Technology, Digital Marketing, Cardiology, Content Marketing, Communications, Health, Convention center, Multimedia, Knowledge, AI, BCEC, Medtronic, Marketing, Medical device

DeviceTalks, a leading multimedia content and event provider for medical device professionals, proudly announces the return of its annual DeviceTalks Boston conference to the Boston Convention & Exhibition Center on May 1-2.

Key Points: 
  • DeviceTalks, a leading multimedia content and event provider for medical device professionals, proudly announces the return of its annual DeviceTalks Boston conference to the Boston Convention & Exhibition Center on May 1-2.
  • “DeviceTalks Boston is a unique opportunity for the forces of Medtech to meet in one place,” said Tom Salemi, editorial director of the digital media business.
  • Highlights of DeviceTalks Boston include:
    Innovation Forum: A centerpiece event led by MedTech Innovator, focusing on funding opportunities and challenges for startups and investors.
  • DeviceTalks Boston also offers exclusive access to the adjacent Robotics Summit & Expo and the inaugural Digital Transformation Forum.

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

Retrieved on: 
목요일, 10월 5, 2023
BCEC, Arthritis, Public, Abstract, Translation studies, Government, Medical Affairs Bureau, Boston Convention and Exhibition Center, Poster, Convention center, Science, Pharmaceutical industry, Nightclub, Skin

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.

Key Points: 
  • BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.
  • The hybrid conference will be held from Oct. 11–15 at the Boston Convention and Exhibition Center.
  • All IDWeek abstracts are embargoed until Oct. 11 at 8:00 a.m.
  • Medical Affairs learning lounge presentation, "CAP in the outpatient setting: Unmet needs and current treatment challenges," featuring guest speaker Teena Chopra, M.D., M.P.H., on Sat., Oct. 14, 10:15–11:00 a.m. in Learning Lounge 2.

TEC Announces Alliance with Bowie-Cass Electric Cooperative

Retrieved on: 
목요일, 8월 24, 2023
Deep East Texas Electric Cooperative, BCEC, Bowie-Cass Electric Cooperative, TEC, Franklin, Nightclub

AUSTIN, Texas, Aug. 24, 2023 /PRNewswire/ -- Texas Electric Cooperatives (TEC) leadership has announced a new sole source alliance with Bowie-Cass Electric Cooperative (BCEC). BCEC serves members in Bowie, Cass, Titus, Morris, Red River, and Franklin Counties and is headquartered in Douglassville, Texas. Wiith a service area that spans over 4500 square miles BCEC services 39,352 connected meters and 6,869.95 miles of line.

Key Points: 
  • AUSTIN, Texas, Aug. 24, 2023 /PRNewswire/ -- Texas Electric Cooperatives (TEC) leadership has announced a new sole source alliance with Bowie-Cass Electric Cooperative (BCEC).
  • BCEC was formed as a cooperative in 1937 and is proud to be owned by the members they serve.
  • An alliance with TEC helps us better manage the challenges of today's supply chain so we can continue serving the members who depend on us to keep the lights on."
  • "TEC will manage the entire supply chain on behalf of BCEC and the rest of our alliance members.

NAACP Utilizes Meridia's Electronic Voting Clickers Again During Their 114th Annual Convention

Retrieved on: 
수요일, 8월 9, 2023
Resolution, Boston Convention and Exhibition Center, BCEC, Environmental protection, Police, Convention center, NAACP, Whaling, Meridia

MALVERN, Pa., Aug. 9, 2023 /PRNewswire-PRWeb/ -- Just like last year in Atlantic City, NJ Meridia's electronic voting clickers replaced a longstanding tradition of paper ballots and manual vote-counting from yesteryears. The week-long event ran from July 28th to August 1st in Boston, covering issues like LGBTQ+ rights, Gun Control, Environmental Protection, Police Training and many other hot-button topics.

Key Points: 
  • The NAACP utilized Meridia's electronic voting platform to collect, count and document the ballots of over 1,300 delegates appointed from each of the nation's regions during their 114th annual convention hosted this year at the Boston Convention and Exhibition Center (BCEC).
  • The voting system allowed the NAACP to conduct business meeting voting quickly, accurately, and securely during their Resolutions Plenary session.
  • Leon W. Russell, (NAACP Chair) led the meeting and verbally opened and closed each vote.
  • MALVERN, Pa., Aug. 9, 2023 /PRNewswire-PRWeb/ -- Just like last year in Atlantic City, NJ Meridia's electronic voting clickers replaced a longstanding tradition of paper ballots and manual vote-counting from yesteryears.

CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5

Retrieved on: 
금요일, 6월 2, 2023
BIO, BCH, Road, Super Session, Exhibition, MB, Disease, Biotechnology, Huntington Avenue, Brigham and Women's Hospital, Health, Boston Convention and Exhibition Center, Research, Doctor of Philosophy, Michigan Biotechnology Institute, EDT, Harvard Medical School, BCEC, BAO, Pandemic, MD, JD, ABC, Coffee, Convention center, Neurology, ESG, Digital, Foreign policy, Ecosystem, AI, Alzheimer's disease, Hospital, Woman, WIB, Pharmaceutical industry, Organon, Cure

NEW YORK, June 2, 2023 /PRNewswire/ -- Cure®, a healthcare innovation campus in New York City, today announced a one-of-a-kind Super Session featuring experts focused on leveraging AI for good as part of the company's presence at the Biotechnology International Convention, the largest global event for the biotech industry, in Boston, MA. from June 5 to 8, 2023.

Key Points: 
  • "The dizzying array of things AI can seemingly do – good, great, and worrisome – has the world of healthcare both excited and overwhelmed.
  • For the BIO Super Session, the panel Cure has gathered will discuss how we can optimally leverage AI and other advanced technologies while mitigating risks," said Cure Chief Executive Officer Seema Kumar.
  • The Cure booth also will host Cure Studios on the Road, capturing highlights and insights from leading biotech executives.
  • The booth will be open 8:00 am to 5:00 pm EDT in the BCEC Ground Level Halls A-C from June 5 to 8, 2023.